drugset / Trial / NCT03068247

Neurobiology of Treatment Responses in MDD

NCT03068247

Phase 3 Withdrawn University of Utah
RandomizedParallel-groupQuadruple-blindOther

Summary

The primary study intent is to examine biological mechanisms associated with acute and chronic treatment responses in major depressive disorder (MDD). It is hypothesized that treatment responsiveness, representing endogenous opioid system function, will be associated with acute improvements in mood state over a 10-week treatment trial in MDD. Potential (bio) markers of treatment effects will be tested against psychophysical responses to placebo and active treatments.

Timeline

Start
2021-11
Primary completion
2023-05
Completion
2023-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral